Endothelin-mediated remodeling in aortas of diabetic rats

被引:34
作者
Fukuda, G
Khan, ZA
Barbin, YP
Farhangkhoee, H
Tilton, RG
Chakrabarti, S
机构
[1] Univ Western Ontario, Dept Pathol, London, ON N6A 5C1, Canada
[2] Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77550 USA
关键词
macroangiopathy; endothelins; extracellular matrix; oncofetal fibronectin; SMemb;
D O I
10.1002/dmrr.527
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Smooth muscle cells proliferation and extracellular matrix (ECM) protein deposition are key features of diabetic macroangiopathy. In the present study, we have studied the role of endothelin(A) (ETA) receptor, the predominant receptor on smooth muscle cells, in diabetes-induced vascular hypertrophy and remodeling. Methods Streptozotocin-induced diabetic rats were administrated a selective ETA receptor antagonist, TBC3214, for 26 weeks. Following treatment, aortas were harvested and subjected to gene expression and morphometric analyses. We quantified fibronectin (FN) and plasminogen activator inhibitor-1 (PAI-1) expression as indicators of increased ECM protein synthesis. ET-1, ET-3, transforming growth factor-beta 1 (TGF-beta 1) and angiotensinogen mRNA levels were measured to elucidate genes involved in FN expression. We have investigated an embryonic splice variant of FN, oncofetal FN, and nonmuscle myosin heavy chain (SMemb) as vascular remodeling indicators. Results Our results show that diabetes leads to upregulation of FN, PAI-1, ET-1, ET-3, TGF-beta 1 and angiotensinogen mRNA levels in association with increased medial thickness. Immunohistochemical analyses revealed concurrent protein level changes. Diabetes also upregulated oncofetal FN and SMemb mRNA levels. Treatment with TBC3214 attenuated the mRNA levels of several genes and prevented increased medial thickness. Conclusions These results indicate that diabetes-induced vascular hypertrophy and remodeling is associated with reexpression of embryonic forms of FN and myosin heavy chain. Such changes are ET-dependent and may be mediated via TGF-beta 1 and angiotensin. Copyright (C) 2004 John Wiley & Sons, Ltd.
引用
收藏
页码:367 / 375
页数:9
相关论文
共 51 条
[1]   HUMAN SMOOTH-MUSCLE MYOSIN HEAVY-CHAIN ISOFORMS AS MOLECULAR MARKERS FOR VASCULAR DEVELOPMENT AND ATHEROSCLEROSIS [J].
AIKAWA, M ;
SIVAM, PN ;
KUROO, M ;
KIMURA, K ;
NAKAHARA, K ;
TAKEWAKI, S ;
UEDA, M ;
YAMAGUCHI, H ;
YAZAKI, Y ;
PERIASAMY, M ;
NAGAI, R .
CIRCULATION RESEARCH, 1993, 73 (06) :1000-1012
[2]  
Alessandri G, 1998, LAB INVEST, V78, P127
[3]   A SPECIFIC ENDOTHELIN SUBTYPE-A RECEPTOR ANTAGONIST PROTECTS AGAINST INJURY IN RENAL-DISEASE PROGRESSION [J].
BENIGNI, A ;
ZOJA, C ;
CORNA, D ;
ORISIO, S ;
LONGARETTI, L ;
BERTANI, T ;
REMUZZI, G .
KIDNEY INTERNATIONAL, 1993, 44 (02) :440-444
[4]  
BORDER WA, 1994, NEW ENGL J MED, V331, P1286
[5]   Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action [J].
Cao, ZM ;
Hulthén, UL ;
Allen, TJ ;
Cooper, ME .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :793-799
[6]   The angiogenesis marker ED-B plus fibronectin isoform in intracranial meningiomas [J].
Castellani, P ;
Dorcaratto, A ;
Pau, A ;
Nicola, M ;
Siri, A ;
Gasparetto, B ;
Zardi, L ;
Viale, G .
ACTA NEUROCHIRURGICA, 2000, 142 (03) :277-282
[7]  
Chakrabarti Subrata, 2002, Int J Exp Diabetes Res, V3, P217, DOI 10.1080/15604280214939
[8]   Diabetes-induced myocardial structural changes: Role of endothelin-1 and its receptors [J].
Chen, S ;
Evans, T ;
Mukherjee, K ;
Karmazyn, M ;
Chakrabarti, S .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (09) :1621-1629
[9]   Hyperhexosemia induced functional and structural changes in the kidneys: Role of endothelins [J].
Chen, S ;
Evans, T ;
Deng, D ;
Cukiernik, M ;
Chakrabarti, S .
NEPHRON, 2002, 90 (01) :86-94
[10]   Differential activation of NF-κB and AP-1 in increased fibronectin synthesis in target organs of diabetic complications [J].
Chen, SL ;
Khan, ZA ;
Cukiernik, M ;
Chakrabarti, S .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (06) :E1089-E1097